REG - Smith & Nephew Plc - Director/PDMR Shareholding

Smith & NephewAnnouncement

08/03/2021 11:35

RNS Number : 5024R
  
Smith & Nephew Plc
  
08 March 2021
  
 

SMITH & NEPHEW PLC
 
8 March 2021
 
NOTIFICATION AND PUBLIC DISCLOSURE IN ACCORDANCE WITH THE REQUIREMENTS OF THE EU MARKET ABUSE REGULATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES ("PDMR") AND PERSONS CLOSELY ASSOCIATED WITH THEM.
 



Reason for the notification




Initial notification /Amendment


Initial notification




Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




Name


Smith & Nephew plc




LEI


213800ZTMDN8S67S1H61




Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




Description of the financial instrument, type of instrument
 


Smith & Nephew plc ordinary shares of USD 0.20 each




Identification code


ISIN: GB0009223206




Nature of the transaction


Sale of ordinary shares.




Date of Transaction


2021 - 03 - 05




Place of Transaction


London Stock Exchange (XLON)



 



Name (Position)


Director / PDMR


Price (£)


Volume


Aggregated information


Total Ordinary Share Holding following the transaction *


Total Ordinary Share Holding as a % of the Company's ISC following the transaction *




Skip Kiil
(President Orthopaedics)


PDMR


13.532813


15,706


N/A Single Transaction


0.53744 ordinary shares


0.00000%



 
* including those held by Persons Closely Associated with the Director/PDMR. All figures in these columns are stated to 5 decimal places where applicable.
 
Vickie Reuben  
Deputy Company Secretary
Smith & Nephew plc
 
Tel:  +44 (0)1923 477410

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
DSHFLFFLVAITIIL